Annuncio pubblicitario
Italia markets closed
  • Dow Jones

    39.872,99
    +66,22 (+0,17%)
     
  • Nasdaq

    16.832,62
    +37,75 (+0,22%)
     
  • Nikkei 225

    38.946,93
    -122,75 (-0,31%)
     
  • EUR/USD

    1,0859
    -0,0002 (-0,02%)
     
  • Bitcoin EUR

    64.052,23
    +249,51 (+0,39%)
     
  • CMC Crypto 200

    1.515,10
    +26,56 (+1,78%)
     
  • HANG SENG

    19.220,62
    -415,60 (-2,12%)
     
  • S&P 500

    5.321,41
    +13,28 (+0,25%)
     

Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc.

SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take part in the upcoming Cantor Fitzgerald Global Healthcare Conference 2023.

Details of the company's participation are as follows:

  • Cantor Fitzgerald Global Healthcare Conference 2023

  • Format: Fireside Chat with Chief Executive Officer Steven Quay, M.D., Ph.D.

  • Date and Time: Thursday, September 28th at 9:10 A.M. ET

  • Location: New York, NY

ANNUNCIO PUBBLICITARIO

Interested parties may access the live webcast of the fireside chat by visiting the Investors section of the Atossa website at https://investors.atossatherapeutics.com. The webcast replay will be archived on the Atossa website for 90 days following the conclusion of the event.

About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. For more information, please visit www.atossatherapeutics.com.

Contact:
Eric Van Zanten
VP, Investor and Public Relations
610-529-6219
eric.vanzanten@atossainc.com